Literature DB >> 2189073

Diabetes mellitus, the renin-angiotensin system, and angiotensin-converting enzyme inhibition.

S Björck1, M Aurell.   

Abstract

Many traditional antihypertensive drugs are linked to various effects that may cause concern in the hypertensive diabetic patient. The favorable tolerability of angiotensin-converting enzyme (ACE) inhibitors in essential hypertension makes it likely that they will be well tolerated when used in diabetic patients. Data from ongoing studies support the theory that ACE inhibitors lower blood pressure to the same extent in hypertensive diabetics as in patients with essential hypertension. ACE inhibitors do not seem to affect glucose homeostasis adversely; they may even improve glucose tolerance to a small degree. The renal effects of ACE inhibitors in animal experiments suggest a renal-protective effect that can make them especially valuable.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189073     DOI: 10.1159/000186029

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  4 in total

Review 1.  Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus.

Authors:  K L Goa; M Haria; M I Wilde
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

2.  Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve function.

Authors:  E K Maxfield; N E Cameron; M A Cotter; K C Dines
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

3.  Morphometric investigations on intrarenal vessels of streptozotocin-diabetic rats.

Authors:  H Wehner; G Nelischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

4.  Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist.

Authors:  G Crepaldi; A Carraro; E Brocco; L Adezati; D Andreani; G Bompiani; P Brunetti; D Fedele; R Giorgino; G Giustina
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.